article thumbnail

Leading API biologics (protein and peptide) companies in contract marketing

Pharmaceutical Technology

Victoza, Copaxone, Lupron, Zoladex, Sandostatin, and Somatuline are some of the popularly marketed peptide API therapeutic drugs while more than 600 peptide-based pharmacological leads are being investigated worldwide, across various phases of development.

Leads 52
article thumbnail

Leading innovators in pyridine derivatives for the pharmaceutical industry

Pharmaceutical Technology

Pyridine derivatives contain one nitrogen atom in a six-membered aromatic ring and are the most extensively used heterocycles in the field of drug design, due to their promising effect on pharmacological activity, which has led to the discovery of numerous broad-spectrum therapeutic agents.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Strategies for Streamlining Small Molecule Formulation Development When Bridging from Candidate Selection to First-in-Human Clinical Testing

Pharmaceutical Technology

By associating molecular properties with in-silico absorption, distribution, metabolism, excretion, and toxicity (ADMET) models, we can significantly increase the robustness of candidate selection, which subsequently reduces the failure rate during clinical trials.

article thumbnail

What Is OEM Sales? With Sean Pitts

Evolve Your Success

The OEM acronym is for Original Equipment Manufacturer. We are a manufacturer of supporting components or devices, which we will get into, that support their medical device in the field. You are a manufacturer of field ultrasound systems or even ultrasound systems in a hospital. W hat exactly is OEM sales? COVID was part of it.

Sales 64
article thumbnail

Why R&D innovation holds the key to greater patient impact

European Pharmaceutical Review

Clinical innovation: using digital solutions to deliver the next wave of medicines Strategic collaborations can leverage well-developed infrastructures to develop, manufacture and commercialise medicines in new developing markets, driving a broader distribution of treatments.